Bayer Execs Roth And Eckhardt On Current And Future Pharma Growth

Nubeqa, Kerendia Driving Revenue; New Launches On The Way

 
• By Mandy Jackson
  
New launches and added indications will fuel growth in 2025 as Xarelto revenue declines (Shutterstock)

More from Strategy

More from Scrip